TLR Agonists and Immunotherapy Synergy: Expanding the Reach of Cancer Treatment

TLR Agonists and Immunotherapy Synergy: Cancer immunotherapy has transformed treatment paradigms, yet a large proportion of patients fail to respond to immune checkpoint inhibitors due to an immunologically “cold” tumor microenvironment. Toll-like receptor (TLR) agonists have emerged as promising agents capable of reprogramming the tumor microenvironment by enhancing antigen presentation, inducing type I interferons, and recruiting cytotoxic T cells. When combined with checkpoint inhibitors, TLR agonists can convert resistant tumors into responsive ones, broadening the reach of immunotherapy. Recent clinical studies demonstrate encouraging activity in refractory cancers, with manageable safety profiles and innovative delivery strategies such as intratumoral administration and immunostimulatory antibody conjugates. As the field advances, biomarker-guided trials and next-generation formulations will be essential in unlocking the full potential of TLR agonists in cancer therapy.

Introduction: Why the Tumor Microenvironment Matters

One of the central challenges in modern oncology is the highly variable response to immunotherapy. Immune checkpoint inhibitors (ICIs), such as anti–PD-1 and anti–CTLA-4 antibodies, have revolutionized treatment for cancers like melanoma, lung cancer, and renal cell carcinoma. Yet, a significant proportion of patients either do not respond initially or develop resistance over time. Understanding this heterogeneity has led researchers to focus on the concept of the tumor microenvironment (TME), a dynamic ecosystem where cancer cells interact with immune and stromal elements.

Tumors are often described as “cold” or “hot” based on their immune activity. Cold tumors are characterized by low T-cell infiltration, limited antigen presentation, and an immunosuppressive milieu. These tumors are typically resistant to ICIs, as there are few activated immune cells for checkpoint blockade to unleash. In contrast, hot tumors display robust T-cell infiltration, high levels of inflammatory cytokines, and active antigen presentation—conditions that make them more responsive to immunotherapy. The ability to transform a cold tumor into a hot one is therefore a major therapeutic goal.

Within this context, Toll-like receptors (TLRs) have emerged as attractive targets. TLRs are pattern recognition receptors that detect microbial components and damaged cell signals, initiating strong innate immune responses. Their activation leads to the production of type I interferons, pro-inflammatory cytokines, and chemokines that attract and activate dendritic cells and cytotoxic T lymphocytes. By engaging these pathways, TLR agonists can act as immune “primers,” reshaping the TME to support an effective anti-tumor immune response.

This mechanism is especially relevant in combination with ICIs. While checkpoint inhibitors work by releasing the brakes on T cells, their efficacy depends on having a pre-existing immune response. TLR agonists can provide the necessary spark—enhancing antigen presentation, increasing T-cell trafficking, and boosting effector cell activity. Early clinical studies have shown that these agents can induce systemic immune activation and, in some cases, trigger regression in both injected and distant tumors.

As the field of cancer immunotherapy evolves, reprogramming the TME with TLR agonists represents a promising strategy to expand the benefits of ICIs to a broader population of patients. The next step lies in translating these biological insights into durable clinical outcomes.

The Science Behind Toll-Like Receptors in Cancer

To understand why Toll-like receptor (TLR) agonists are attracting so much attention in oncology, it is important to look at the biology behind these receptors. TLRs are a family of pattern recognition receptors (PRRs) that detect conserved molecular signatures from pathogens—such as bacterial lipopolysaccharides, viral RNA, or unmethylated CpG DNA—as well as danger signals released by stressed or dying cells. Their primary role is to act as sentinels of the innate immune system, initiating responses that shape downstream adaptive immunity.

TLRs are expressed on both immune and non-immune cells, but their localization helps define their function. Surface TLRs (including TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10) typically recognize microbial lipids and proteins. Endosomal TLRs (TLR3, TLR7, TLR8, and TLR9) sense nucleic acids from viruses and bacteria. Once activated, these receptors trigger signaling cascades through adaptor molecules like MyD88 or TRIF, leading to the activation of NF-κB, IRF3, and IRF7. The result is the production of type I interferons and pro-inflammatory cytokines such as IL-6 and TNF-α, which play central roles in bridging innate and adaptive immune responses.

In the context of cancer, TLR signaling can profoundly influence the tumor microenvironment (TME). On the positive side, activation of dendritic cells via TLR agonists enhances antigen presentation and cross-priming of cytotoxic CD8⁺ T lymphocytes, both of which are critical for anti-tumor immunity. TLR activation also induces chemokines such as CXCL9 and CXCL10, which recruit effector T cells into the tumor. This can transform an immunologically “cold” tumor into a “hot” one, creating conditions that make immune checkpoint blockade more effective.

However, TLR biology is not one-sided. Depending on the context, certain TLR pathways can promote tumor progression by fostering chronic inflammation, angiogenesis, and immunosuppressive cytokine release. For example, TLR4 activation has been linked to tumor growth and metastasis in some models. This dual nature underscores the need for careful selection of agonist type, delivery route, and combination strategies in clinical development.

Fig. 1 Hypothesized mechanism for synergism between TLR agonists and immune checkpoint inhibitors in enhancing antitumor immunity.

Ultimately, the rationale for using TLR agonists in oncology lies in their ability to jump-start immune activation and remodel the TME in favor of anti-tumor responses. By leveraging their natural role as innate immune sentinels, these agents offer a way to boost the effectiveness of existing immunotherapies and expand their benefits to resistant patient populations.

Clinical Progress: Where TLR Agonists Stand Today

While Toll-like receptors (TLRs) have been studied for decades as part of the innate immune system, their translation into cancer therapies has only gained significant traction in the last 20 years. Several TLR agonists have already reached clinical practice, while many more are advancing through clinical trials, particularly in combination with immune checkpoint inhibitors (ICIs).

Approved therapies provide proof-of-concept. The earliest success story is bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium bovis that activates TLR2 and TLR4. BCG has been the standard of care for non-muscle invasive bladder cancer for decades, demonstrating how local innate immune activation can produce long-lasting anti-tumor effects. Similarly, imiquimod, a TLR7 agonist cream, is approved for superficial basal cell carcinoma and other skin lesions, while monophosphoryl lipid A (MPLA), a TLR4 agonist, is incorporated into vaccine adjuvants. These examples validate TLR agonism as a viable therapeutic mechanism.

The current clinical landscape is diverse. Ongoing studies are evaluating multiple TLR targets, delivery routes, and cancer types. TLR7 agonists such as BNT411 and DSP-0509 are being tested in solid tumors, often in combination with PD-1 blockade. Dual TLR7/8 agonists, including BDB001 and BDC-1001 (a HER2-targeted immunostimulatory antibody conjugate, or ISAC), are showing early signs of immune activation and disease control in patients with advanced cancers.

Perhaps the most clinically advanced programs are TLR9 agonists, which include CMP-001 (vidutolimod), tilsotolimod, and cavrotolimod. These agents are primarily delivered via intratumoral injection to maximize local immune activation while limiting systemic side effects. Early-phase trials in melanoma and head and neck cancers have shown that TLR9 agonists can induce responses even in patients who are refractory to PD-1 inhibitors. Importantly, regression has been observed not only in injected lesions but also in distant, non-injected tumors, suggesting the induction of systemic immunity.

Safety has been generally manageable. Most TLR agonists cause flu-like symptoms, injection site reactions, fatigue, and transient lymphopenia—consistent with their immune-activating mechanism. When combined with ICIs, toxicity profiles have often been similar to ICI monotherapy, though some programs have been discontinued due to lack of efficacy rather than safety concerns.

Overall, the clinical progress to date highlights the potential of TLR agonists to extend the benefits of immunotherapy. By turning immunologically “cold” tumors into “hot” ones, these agents may broaden the pool of patients who can benefit from checkpoint blockade.

Combination with Checkpoint Inhibitors: Unlocking Non-Responders

Immune checkpoint inhibitors (ICIs) such as anti–PD-1, anti–PD-L1, and anti–CTLA-4 antibodies have transformed the landscape of cancer treatment. However, their benefits are still limited to a subset of patients, leaving many with minimal or no response. A key determinant of success is the presence of a pre-existing immune response in the tumor microenvironment (TME). Tumors rich in cytotoxic T cells and inflammatory signals—so-called “hot” tumors—tend to respond to checkpoint blockade, while “cold” tumors with poor immune infiltration often resist therapy. This limitation has spurred interest in pairing ICIs with agents that can ignite immune activity, and Toll-like receptor (TLR) agonists are emerging as strong candidates.

The rationale for combining TLR agonists with ICIs rests on complementary mechanisms. TLR activation boosts innate immunity by stimulating dendritic cells, enhancing antigen presentation, and inducing cytokines like interferon-α and CXCL10, which attract effector T cells. This immune priming can convert cold tumors into hot ones, setting the stage for checkpoint inhibitors to work more effectively. ICIs then sustain and amplify the T-cell attack by preventing exhaustion and restoring effector function. Together, these approaches address both the initiation and maintenance of anti-tumor immunity.

Clinical evidence supports this synergy. Intratumoral TLR9 agonists such as CMP-001 and cavrotolimod have shown promising results in PD-1–refractory melanoma when combined with PD-1 inhibitors, producing objective responses in patients who had previously failed immunotherapy. Importantly, some studies have documented regression in both injected and distant, non-injected lesions, highlighting systemic immune activation. TLR7/8 agonists and immunostimulatory antibody conjugates (ISACs) are also being investigated in combination with checkpoint blockade, with early data suggesting enhanced immune responses without significant increases in toxicity compared to ICI monotherapy.

Safety considerations remain important. While TLR agonists can cause flu-like symptoms, fatigue, and injection-site reactions, these side effects are usually manageable and transient. Most importantly, early combination trials indicate that pairing TLR agonists with ICIs does not substantially exacerbate immune-related adverse events, making the combination clinically feasible.

The promise of TLR agonists lies in their ability to expand the reach of ICIs beyond the current pool of responders. By reshaping the TME and providing the “spark” needed to activate immune responses, these agents may unlock durable benefit for patients with resistant or poorly inflamed tumors.

Future Outlook: Challenges and Opportunities

The development of Toll-like receptor (TLR) agonists as cancer therapeutics has generated significant enthusiasm, particularly in combination with immune checkpoint inhibitors (ICIs). Still, as this field matures, researchers face both opportunities and challenges in turning early clinical promise into widespread benefit.

One of the most pressing questions is how to optimize patient selection. Not all tumors will respond equally to TLR agonists, and identifying biomarkers that predict benefit will be crucial. For example, dendritic cell activation profiles, T-cell infiltration levels, and tumor antigen expression may all help guide treatment strategies. Future trials are increasingly focusing on biomarker-driven enrollment, which could sharpen therapeutic efficacy while minimizing unnecessary toxicity.

Another area of opportunity lies in innovative drug design. Early agonists were often non-specific and systemically delivered, raising concerns about off-target inflammation. Newer strategies, such as immunostimulatory antibody conjugates (ISACs), link TLR agonists directly to tumor-targeting antibodies, enabling localized immune activation within the tumor microenvironment. Similarly, intratumoral injection strategies are being refined to maximize efficacy while reducing systemic side effects. These approaches could overcome some of the limitations observed in earlier clinical trials.

Safety management will continue to play a central role. While most adverse effects are consistent with immune stimulation—flu-like symptoms, fatigue, and local injection reactions—balancing immune activation with tolerability remains essential. The good news is that, so far, combinations with ICIs have not consistently produced severe additive toxicity. Continued monitoring and long-term follow-up, however, will be necessary to confirm safety as these therapies move into larger patient populations.

Looking forward, the trial design landscape is also evolving. Adaptive clinical trial models and combination regimens beyond ICIs—such as pairing TLR agonists with radiation therapy, cancer vaccines, or even CAR-T therapies—are being explored. These multimodal strategies may further enhance immune priming and broaden the spectrum of responsive tumors.